Bruker Corporation has unveiled the timsOmni™ system, a groundbreaking mass spectrometer designed to revolutionize scientific research and drug discovery. This timsTOF-based instrument offers unparalleled speed and sensitivity, providing deep structural insights into functional and pathological proteoforms. Notable for its 'Swiss Army Knife' flexibility, the timsOmni facilitates advanced electron and collision induced ion fragmentation, aiding in proteoform sequencing and post-translational modification identification. This novel platform is set to transform disease research, biologics development, and quality control processes, offering critical insights into the structural changes of proteins associated with diseases such as cancer and neurodegeneration.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.